Understanding PIRA in MS: Key Insights and Advances From ECTRIMS 2024
December 3rd 2024Panelists discuss how progression independent of relapse activity (PIRA) in multiple sclerosis (MS) represents continuous neurological decline unrelated to inflammatory events, distinct from relapse-associated worsening (RAW). Recent ECTRIMS 2024 presentations emphasized standardized evaluation methods to better understand disease progression and improve patient management strategies.
The Impact of Biomarkers and Modern Disease-Modifying Therapies in MS
December 3rd 2024Panelists discuss how modern multiple sclerosis (MS) management has evolved from symptomatic treatment to a proactive, personalized approach leveraging advanced biomarkers and sophisticated disease-modifying therapies. The focus has shifted toward early intervention, precise monitoring, and comprehensive disease control, significantly improving patient outcomes and quality of life.
Important Considerations for Infantile Spasms Awareness: Martina Bebin, MD, MPA
December 3rd 2024The professor of neurology at the University of Alabama at Birmingham Epilepsy Center provided comment on raising awareness for infantile spasms, especially during Infantile Spams Awareness Week, which is celebrated the first week of December. [WATCH TIME: 3 minutes]
Exploring Gaps in RLS Treatment Through New 2024 Guidelines: Andy Berkowski, MD, PhD
December 3rd 2024The vice chair of the American Academy of Sleep Medicine’s Clinical Practice Guidelines Task Force commented on some of the unanswered questions following the recently published guidelines for restless legs syndrome. [WATCH TIME: 3 minutes]
Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management
December 2nd 2024A panelist discusses how comparing hospitalization rates, relapse risks, and safety considerations between rituximab and other NMOSD therapies, such as complement inhibitors, can provide valuable insights to guide treatment decisions, manage healthcare costs, and optimize patient quality of life.
Importance of Genetic Counseling and Next-Generation Sequencing for Pediatric Epilepsy Diagnosis
November 28th 2024John Michael Schreiber, MD, describes how he counsels and educates caregivers about the potential benefits and limitations of genetic testing, detailing his approach to educating them before testing, how he guides them in interpreting results and transitioning to clinical management afterward, and the role of genetic counseling, including when to refer to a genetic specialist; he also provides key takeaways on the role and value of genetic testing for pediatric epilepsy and discusses how providers should utilize next-generation sequencing (NGS) moving forward.
Collaboration and Innovation in Alzheimer Disease Clinical Trial Research: Howard Fillit, MD
November 26th 2024The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation highlighted the critical role of collaboration and innovative diagnostics for advancing Alzheimer disease care. [WATCH TIME: 4 minutes]
Assessing Omaveloxolone’s Positive Long-Term Safety Profile: David Lynch, MD, PhD
November 26th 2024The professor of neurology at the University of Pennsylvania Perelman School of Medicine provided clinical insight on a long-term safety analysis of omaveloxolone, the first FDA-approved treatment for Friedreich ataxia. [WATCH TIME: 4 minutes]
Shared Decision-making for Selection of FDA-approved Therapies for NMOSD
November 25th 2024A panelist discusses how when treating NMOSD, neurologists should consider the patient's clinical characteristics, safety profiles, administration requirements, and cost-effectiveness when selecting between FDA-approved therapies such as eculizumab, inebilizumab, satralizumab, ravulizumab, and rituximab. Shared decision-making is crucial, involving close collaboration between the healthcare team and the patient to develop a personalized treatment plan that considers the patient's overall well-being.
Overviewing Major Changes to the 2024 Restless Legs Syndrome Guidelines: Andy Berkowski, MD, PhD
November 25th 2024The vice chair of the American Academy of Sleep Medicine’s Clinical Practice Guidelines Task Force provided in-depth insight on the most noted changes to the 2024 RLS guidelines clinicians should be aware of. [WATCH TIME: 9 minutes]
Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD
November 21st 2024The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]
Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MD
November 21st 2024The neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]
Importance of Genetic Testing for Pediatric Epilepsy Diagnosis and Treatment Decisions
November 21st 2024John Michael Schreiber, MD, describes the benefits of genetic testing for pediatric epilepsy diagnoses, noting the challenges associated with interpreting test results, and highlights key differences between genetic tests and their implications for clinical decisions, discussing how a genetic diagnosis can inform and guide epilepsy treatment.
Scalability of Scalp EEG as a Tool for Epilepsy Surgery Outcomes: Lara Jehi, MD, MHCDS
November 21st 2024The epilepsy specialist and Cleveland Clinic’s Chief Research and Information Officer discussed the wide-spread applicability of scalp EEG and the potential for machine learning models to help predict epilepsy surgery outcomes. [WATCH TIME: 4 minutes]
Driving Innovation in Aging and Neurodegenerative Research: Henri Ford, MD, MHA
November 20th 2024The dean and chief academic officer at the University of Miami Miller School of Medicine discussed the university’s investment in computational biology to advance aging and neuroscience research. [WATCH TIME: 5 minutes]
Current Treatment Landscape of AQP4-IgG+ NMOSD and Considerations on Relapse Rates
November 18th 2024Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system. Anti-CD20 therapies, particularly rituximab, have led to increased relapse rates.
Using Data Collection to Improve Parkinson Disease Treatment Personalization: Amanda Hare, DNP
November 14th 2024The doctor of nursing practice specialized in movement disorders discussed specific data the StrivePD app captures and how it can enhance quality of life for patients with Parkinson disease. [WATCH TIME: 3 minutes]
Key Considerations for Genetic Testing Selection in Pediatric Patients with Epilepsy
November 14th 2024John Michael Schreiber, MD, expands on the role of genetic testing in identifying and diagnosing epilepsy, discussing when it is clinically indicated and who should receive it, while also addressing key considerations for selecting tests for pediatric patients based on individual presentations and clinical factors, and outlining how to choose the best testing options while recognizing potential barriers and expectations for health care providers, caregivers, and patients before and after testing.
Educational Benefits of Flipped Classrooms in Teaching Settings: Lawrence Robinson, MD
November 13th 2024The senior scientist at Sunnybrook Research Institute in Toronto, Ontario, provided clinical insight on the advantages of a flipped classroom, and why neurology educators should consider this approach. [WATCH TIME: 2 minutes]
Therapeutic Advantages of StrivePD for Parkinson Disease Management: Amanda Hare, DNP
November 13th 2024The doctor of nursing practice specialized in movement disorders provided clinical insight on how the StrivePD application empowers patients with Parkinson disease to track symptoms, medication, and daily activities using an iPhone and Apple Watch. [WATCH TIME: 3 minutes]